scholarly journals Differential-diagnostic criteria of active ulcerative colitis and irritable bowel syndrome

2021 ◽  
Vol 90 (1) ◽  
pp. 33-43
Author(s):  
P.P. Snisarevskyi ◽  
O.O. Dyadyk ◽  
A.E. Dorofeyev ◽  
T.P. Snisarevska
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Comparative Analysis ◽  
Diagnostic Criteria ◽  
Large Intestine ◽  
Clinical Laboratory ◽  
Diagnostic Process ◽  
Active Ulcerative Colitis ◽  
Equal Frequency ◽  
Irritable Bowel

The authors conducted a comparative analysis of clinical, laboratory and endoscopic data of 80 patients with ulcerative colitis (UC) of the 1st, 2nd, 3rd degrees of activity and 82 patients with irritable bowel syndrome (IBS) to determine the possible differential-diagnostic criteria of these diseases. It has been found that UC of the 1st, 2nd, 3rd degrees of activity develops with equal frequency among men and women, but IBS develops more often in women. The average age of patients with UC [the 1st degree of activity – (49.1±1.8) years, the 2nd degree of activity – (49.2±1.9) years, the 3rd degree of activity – (49.4±2.5) years] is higher compared to the average age of patients with IBS [(38.4±1.2) years]. UC of the 1st, 2nd, 3rd degrees of activity more often develops in patients after 40 years, while IBS in patients at the age of 18 till 40 years. Pain along the intestine occurs with equal frequency in patients with UC of the 2nd and 3rd degrees of activity. Stool disorders occur with equal frequency in patients with UC of the 1st, 2nd, 3rd degrees of activity and IBS. In a clinical blood test with the same frequency diagnose anemia and increased erythrocyte sedimentation rate in patients with UC of the 2nd and 3rd degrees of activity. Increased level of fecal calprotectin is documented with equal frequency in patients with UC of the 1st, 2nd, 3rd degrees of activity. Bleeding in the large intestine is a characteristic endoscopic finding for patients with UC of the 3rd degree of activity. Erosive-ulcerative changes in the large intestine on endoscopic examination are found with equal frequency in patients with UC of the 1st, 2nd, 3rd degrees of activity. The comparative analysis of clinical, laboratory and endoscopic data in most cases did not allow to identify the clear differential-diagnostic criteria for different degrees of activity of UC, UC and IBS. The data obtained by the authors update the conduct of a comprehensive morphological study, which would identify the specific and clear differential-diagnostic criteria of UC and IBS, which will certainly improve the treatment and diagnostic process among this category of patients and also diseases prognosis. Keywords: differential-diagnostic criteria, active ulcerative colitis, irritable bowel syndrome.

Intraluminal Colonic Release of Immunoreactive Tumour Necrosis Factor in Chronic Ulcerative Colitis

1994 ◽  
Vol 87 (4) ◽  
pp. 453-458 ◽  
Author(s):  
F. Casellas ◽  
M. Papo ◽  
F. Guarner ◽  
M. Antolín ◽  
J. R. Armengol ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Tumour Necrosis Factor ◽  
Chronic Ulcerative Colitis ◽  
Tumour Necrosis ◽  
Active Ulcerative Colitis ◽  
Aminosalicylic Acid ◽  
Irritable Bowel ◽  
Necrosis Factor ◽  
Factor Release

1. Tumour necrosis factor is a proinflammatory macrophage-derived polypeptide cytokine. Its participation in disease processes has been usually inferred from data obtained from experiments in vitro or from measurements of its plasma circulating levels. To investigate its role in chronic ulcerative colitis, we have quantified in vivo the steady-state release of tumour necrosis factor into the colonic lumen. 2. We studied 19 patients with untreated active ulcerative colitis and seven patients with irritable bowel syndrome as controls. A group of seven patients with active ulcerative colitis were studied before and after 4 weeks on treatment with oral 5-aminosalicylic acid. By means of an intracolonic double-lumen perfusion tube, an isotonic solution was continuously infused 50 cm from the anal verge at a rate of 5 ml/min, and was recovered 30 cm distally by siphonage. Effluents were assayed for tumour necrosis factor by a specific e.l.i.s.a. and for prostaglandin E2 and leukotriene B4 by specific r.i.a.s. 3. The intracolonic release of tumour necrosis factor was undetectable in patients with irritable bowel syndrome, whereas measurable release occurred in 15 out of 19 patients with active ulcerative colitis (P < 0.01). Prostaglandin E2 and leukotriene B4 release were also increased in active ulcerative colitis by comparison with irritable bowel syndrome (P < 0.01). Five out of seven patients with colitis improved with 5-aminosalicylic acid treatment, and tumour necrosis factor release became undetectable or decreased markedly (P < 0.05 compared with before treatment). However, tumour necrosis factor release remained high in the non-responder patients. 4. These findings indicate that intracolonic immunoreactive tumour necrosis factor release is enhanced in active chronic ulcerative colitis, becoming undetectable when mucosal lesions are healed. These results suggest that the luminal release of tumour necrosis factor may serve as an objective index of inflammatory activity in patients with chronic ulcerative colitis.

Gut permeability in patients with irritable bowel syndrome and inactive ulcerative colitis

2009 ◽  
Vol 47 (05) ◽  
Author(s):  
K Gecse ◽  
R Róka ◽  
T Séra ◽  
A Annaházi ◽  
A Rosztóczy ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Gut Permeability ◽  
Irritable Bowel

scholarly journals Irritable bowel syndrome-like symptoms associated with endoscopic activity predict ulcerative colitis relapse in patients with clinical remission

2017 ◽  
Vol 15 (4) ◽  
pp. 543 ◽  
Author(s):  
Nobuhiko Fukuba ◽  
Shunji Ishihara ◽  
Kousaku Kawashima ◽  
Yoshiyuki Mishima ◽  
Naoki Oshima ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Clinical Remission ◽  
Irritable Bowel

scholarly journals Taxonomic composition and biodiversity of the gut microbiome from patients with irritable bowel syndrome, ulcerative colitis, and asthma

2022 ◽  
Vol 25 (8) ◽  
pp. 864-873
Author(s):  
A. Y. Tikunov ◽  
A. N. Shvalov ◽  
V. V. Morozov ◽  
I. V. Babkin ◽  
G. V. Seledtsova ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Gut Microbiome ◽  
Taxonomic Composition ◽  
16S Rrna Genes ◽  
Rrna Genes ◽  
Taxonomic Structure ◽  
Opportunistic Bacteria ◽  
Irritable Bowel

To date, the association of an imbalance of the intestinal microbiota with various human diseases, including both diseases of the gastrointestinal tract and disorders of the immune system, has been shown. However, despite the huge amount of accumulated data, many key questions still remain unanswered. Given limited data on the composition of the gut microbiota in patients with ulcerative colitis (UC) and irritable bowel syndrome (IBS) from different parts of Siberia, as well as the lack of data on the gut microbiota of patients with bronchial asthma (BA), the aim of the study was to assess the biodiversity of the gut microbiota of patients with IBS, UC and BA in comparison with those of healthy volunteers (HV). In this study, a comparative assessment of the biodiversity and taxonomic structure of gut microbiome was conducted based on the sequencing of 16S rRNA genes obtained from fecal samples of patients with IBS, UC, BA and volunteers. Sequences of the Firmicutes and Bacteroidetes types dominated in all samples studied. The third most common in all samples were sequences of the Proteobacteria type, which contains pathogenic and opportunistic bacteria. Sequences of the Actinobacteria type were, on average, the fourth most common. The results showed the presence of dysbiosis in the samples from patients compared to the sample from HVs. The ratio of Firmicutes/Bacteroidetes was lower in the IBS and UC samples than in HV and higher the BA samples. In the samples from patients with intestinal diseases (IBS and UC), an increase in the proportion of sequences of the Bacteroidetes type and a decrease in the proportion of sequences of the Clostridia class, as well as the Ruminococcaceae, but not Erysipelotrichaceae family, were found. The IBS, UC, and BA samples had signif icantly more Proteobacteria sequences, including Methylobacterium, Sphingomonas, Parasutterella, Halomonas, Vibrio, as well as Escherichia spp. and Shigella spp. In the gut microbiota of adults with BA, a decrease in the proportion of Roseburia, Lachnospira, Veillonella sequences was detected, but the share of Faecalibacterium and Lactobacillus sequences was the same as in healthy individuals. A signif icant increase in the proportion of Halomonas and Vibrio sequences in the gut microbiota in patients with BA has been described for the f irst time.

scholarly journals FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms

2015 ◽  
Vol 52 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Lorete Maria da Silva KOTZE ◽  
Renato Mitsunori NISIHARA ◽  
Sandra Beatriz MARION ◽  
Murilo Franco CAVASSANI ◽  
Paulo Gustavo KOTZE
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Inflammatory Bowel Diseases ◽  
Fecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Active Disease

Background Determination of fecal calprotectin can provide an important guidance for the physician, also in primary care, in the differential diagnosis of gastrointestinal disorders, meanly between inflammatory bowel diseases and irritable bowel syndrome. Objectives The aims of the present study were to prospectively investigate, in Brazilian adults with gastrointestinal complaints, the value of fecal calprotectin as a biomarker for the differential diagnosis between functional and organic disorders and to correlate the concentrations with the activity of inflammatory bowel diseases. Methods The study included consecutive patients who had gastrointestinal complaints in which the measurement levels of fecal calprotectin were recommended. Fecal calprotectin was measured using a Bühlmann (Basel, Switzerland) ELISA kit Results A total of 279 patients were included in the study, with median age of 39 years (range, 18 to 78 years). After clinical and laboratorial evaluation and considering the final diagnosis, patients were allocated into the following groups: a) Irritable Bowel Syndrome: 154 patients (102 female and 52 male subjects). b) Inflammatory Bowel Diseases group: 112 patients; 73 with Crohn’s disease; 38 female and 35 male patients; 52.1% (38/73) presented active disease, and 47.9% (35/73) had disease in remission and 39 patients with ulcerative colitis;19 female and 20 male patients; 48.7% (19/39) classified with active disease and 49.3% (20/39) with disease in remission. A significant difference (P<0.001) was observed between the median value of fecal calprotectin in Irritable Bowel Syndrome group that was 50.5 µg/g (IQR=16 - 294 µg/g); 405 µg/g (IQR=29 - 1980 µg/g) in Crohn’s disease patients and 457 µg/g (IQR=25 - 1430 µg/g) in ulcerative colitis patients. No difference was observed between the values found in the patients with Crohn’s disease and ulcerative colitis. Levels of fecal calprotectin were significantly lower in patients with inflammatory bowel diseases in remission when compared with active disease (P<0.001). Conclusions The present study showed that the determination of fecal calprotectin assists to differentiate between active and inactive inflammatory bowel diseases and between inflammatory bowel diseases and irritable bowel syndrome.

Mo1157 DIFFERENCES IN BRAIN SIGNATURES IN ULCERATIVE COLITIS AND IRRITABLE BOWEL SYNDROME

2020 ◽  
Vol 158 (6) ◽  
pp. S-806
Author(s):  
Joanna Turkiewicz ◽  
Ravi Bhatt ◽  
Beatrix Krause ◽  
Priten Vora ◽  
Arpana Gupta ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document